Cytokinetics (CYTK) Earnings Analysis
Cytokinetics (CYTK) has no confirmed upcoming earnings date. Last quarter (2025-02-27) it beat with EPS -1.26 USD vs -1.29 USD est (+2.3%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -12.03.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CYTK next report earnings?
No confirmed upcoming earnings date is currently scheduled for CYTK. This page updates as the calendar is published.
CYTK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-02-27 | -1.26 USD | -1.29 USD | +2.3% | Beat |
| 2024-08-08 | -1.31 USD | -1.02 USD | -28.4% | Miss |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
CYTK valuation and analyst view
| Trailing P/E | -12.03 |
|---|---|
| Trailing EPS | -6.72986 USD |
| Price / book | -12.26 |
| Dividend yield | 0.00% |
| Market cap | 10.40B |
| Analyst consensus | Buy (34 buy / 1 hold / 0 sell) |
| Avg price target | 116.11 USD |
Related research pages
Frequently asked questions
When is Cytokinetics (CYTK)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CYTK. This page updates as the calendar is published.
Did CYTK beat earnings last quarter?
In its 2025-02-27 report, CYTK posted EPS of -1.26 USD versus a -1.29 USD estimate — a beat of 2.3%.
What is CYTK's earnings track record?
Over the last 2 reported quarters with consensus data, CYTK beat estimates 1 times (50%).
What is CYTK's current P/E ratio and EPS?
CYTK trades at a trailing P/E of -12.03 on trailing EPS of -6.729859742198211 USD.
What do analysts rate CYTK?
Analyst consensus is "Buy" across 35 ratings (0 strong buy, 34 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 116.11 USD.